3 completed, 2 unknown, 2 withdrawn, 1 terminated. 4 Phase 1, 3 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Acute Leukemias: new trials by email Literature Review of Acute Leukemias trials Research Report on Acute Leukemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias JNJ-75276617, Fludarabine, Cytarabine - Acute Leukemias, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2025-12-26 | 2025-06-22 | |
| A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia 14C-bleximenib, bleximenib - Acute Lymphoblastic Leukemia, Acute Leukemias | Phase 1 | Completed | Janssen Research & Development, LLC | 6 | 2025-11-18 | 2026-09-25 |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases Fludarabine, Cyclophosphamide, Total Body Irradiation - Acute Leukemias, Burkitt's Lymphoma | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 2 | 2014-10-01 | 2019-12-26 |
| A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene EPZ-5676 - Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | Epizyme, Inc. | 18 | 2014-05-01 | 2023-06-18 |
| Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia LDE225 - Acute Leukemias | Phase 2 | Completed | Novartis Pharmaceuticals | 70 | 2013-05-01 | 2016-08-30 |
| Providing Access to Cord Blood Units for Transplants Access to unlicensed cord blood units - Chronic Myelogous Leukemia/Other Leukemia, Acute Leukemias | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2011-10-27 | 2018-12-21 | |
| Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Busulfan/Cyclophosphamide - Acute Leukemias, Chronic Leukemias | Phase 4 | Unknown | Tel-Aviv Sourasky Medical Center | 10 | 2011-06-01 | 2011-04-21 |
| Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Transplantation of CD3/CD19 depleted stem cells - Acute Leukemias, Aplastic Anemia | Phase 1 / Phase 2 | Unknown | University Children's Hospital Tuebingen | 120 | 2004-03-01 | 2014-10-08 |
Leukemia, Myeloid, Acute (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Anemia, Aplastic (1) · Bone Marrow Failure Disorders (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelomonocytic, Juvenile (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Leukemia, Myeloid (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Leukemia, Lymphoid (5) · Bone Marrow Diseases (4) · Disease Attributes (3) · Leukemia (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
Cyclophosphamide (2) · fludarabine (2) · Busulfan (1) · Cytarabine (1) · Dexamethasone (1) · EPZ-5676 (1) · Vincristine (1) · Whole-Body Irradiation (1) · fludarabine phosphate (1) · pegaspargase (1) · sonidegib (1)
Janssen Research & Development, LLC (2) · Epizyme, Inc. (1) · Masonic Cancer Center, University of Minnesota (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1) · Tel-Aviv Sourasky Medical Center (1) · University Children's Hospital Tuebingen (1)
United States (3) · Austria (2) · Canada (2) · Germany (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Hungary (1) · Netherlands (1) · Norway (1) · Spain (1)
Claudio Brunstein, MD (1) · Cynthia Wetmore, MD PhD (1) · Jim A Whitlock, MD (1) · Lewis Silverman, MD (1) · Lia Gore, MD (1) · Maureen O'Brien, MD (1) · Mignon Loh, MD (1) · Neal Shukla, MD (1) · Pat Brown, MD (1) · Paul Gaynon, MD (1) · Peter Lang, MD (1) · Ronald E Gress, M.D. (1) · Todd Cooper, MD (1)